Zacks Industry Outlook Highlights Intuitive Surgical, Edwards Lifesciences and Electromed
π Zacks Equity Research released an outlook on February 24, 2026, highlighting Intuitive Surgical, Edwards Lifesciences, and Electromed as key players in the medical instruments sector.
π€ Generative AI (GenAI) has transitioned from experimental to operational use in the last 12 months, improving diagnostics, patient monitoring, and intervention workflows across the industry.
π Global AI in healthcare was valued at $39.34 billion in 2025 and is projected to grow at a CAGR of 43.9% through 2034 according to Fortune Business Insights.
β οΈ The industry faces significant challenges including high implementation costs, data breach risks, biased AI outputs, tariffs, staffing shortages, and research funding cuts.
π Regulatory bodies are adapting with the European Commission proposing rule simplifications in December 2025 and the FDA issuing guidance on predetermined change control plans for AI-enabled devices.
π¬ GenAI is reshaping MedTech by speeding up patient recruitment, optimizing trial designs, improving regulatory processes, and enabling hyper-personalized treatment options.
π° Global GenAI in healthcare was valued at $2.65 billion in 2025 and is expected to expand at a CAGR of 35.1% through 2035 with AI diagnostics growing at 46.1%.
π€ The medical instrument sector has benefited from a robust merger and acquisition trend, with deal values rebounding above pre-2023 levels in 2025.
π Spin-offs and divestitures accounted for more than one-third of strategic deal value in the first 11 months of 2025, up from the previous five-year average.
πΌ Major M&A activity included Boston Scientific's $14.5 billion agreement to acquire Penumbra and Danaher's $9.9 billion agreement to acquire Masimo Corp.
π Global economic growth is forecast at 3.3% for 2026 and 3.2% for 2027, marking a slight upward revision for the current year compared to previous estimates.
π Global headline inflation is expected to decline from 4.1% in 2025 to 3.8% in 2026, though emerging markets face slower disinflation than advanced economies.
β οΈ The IMF warns that policy-generated disruptions could interrupt the pivot to easing monetary policy, affecting fiscal sustainability and financial stability.
π Higher nominal wage growth accompanied by weak productivity may make it difficult for firms to moderate price increases, especially when profit margins are squeezed.
π The Zacks Medical Instruments industry carries an upbeat Industry Rank indicating strong near-term prospects despite broader macroeconomic headwinds.
- Generative AI has transitioned from experimental to operational in the last 12 months, improving diagnostics, patient monitoring, and intervention workflows for medical instrument companies.
- Global AI in the healthcare market was estimated at $39.34 billion in 2025 and is projected to grow at a CAGR of 43.9% through 2034.
- Regulatory bodies are adapting proactively, with the European Commission proposing rule simplifications in December 2025 and the FDA issuing guidance on predetermined change control plans in August.
- Hyper-personalization is emerging as a primary feature of GenAI-driven treatment options, enabling predictive treatment and smart hospital systems through vast genetic data analysis.
- Global GenAI in the healthcare market is valued at $2.65 billion in 2025 with a projected CAGR of 35.1% through 2035, while AI in diagnostics specifically is expected to grow at 46.1% by 2034.
- M&A activity shows robust momentum with deal values rebounding above pre-2023 levels in the second half of 2025 and significant transactions like Boston Scientific's $14.5 billion acquisition of Penumbra.
- Global growth is expected to remain steady at 3.3% in 2026, representing a positive upward revision compared to previous forecasts.
- Global headline inflation is expected to decline from 4.1% in 2025 to 3.8% in 2026 as advanced economies reach targets sooner.
- The Zacks Medical Instruments industry carries an upbeat near-term outlook supported by its strong Zacks Industry Rank.
- Broader macroeconomic pressures, including tariffs and staffing shortages, are weighing on the MedTech sector.
- High expenses tied to implementing AI-based solutions, data breach risks, and biased outputs from incomplete or unrepresentative data pose significant operational obstacles for the industry.
- Global growth forecasts remain steady at 3.3% in 2026 and 3.2% in 2027, which could limit expansion potential despite AI-driven optimism.
- Low-income developing countries face sizable downside growth revisions due to increased conflicts and recent tariff shocks.
- Potential policy disruptions to the disinflation process may interrupt the pivot to easing monetary policy, raising concerns about fiscal sustainability.
- Higher nominal wage growth accompanied by weak productivity could make it difficult for firms to moderate price increases when profit margins are already squeezed.
- Despite positive deal-making trends, spin-offs and divestitures accounted for more than a third of strategic deal value in the first 11 months of 2025, potentially fragmenting revenue streams.
- Regulatory bodies are adapting to new AI rules, with the FDA issuing guidance on predetermined change control plans (PCCPs) as part of marketing submissions, introducing potential compliance complexity.